2025年国家医保目录调整的预申报应当已经开始了。4月14日,康诺亚向健识局确认:司普奇拜单抗将参与2025年的国谈。这是第一个获批的国产IL-4单抗,去年9月,司普奇拜单抗首次获批成人中重度特应性皮炎,没能赶上那一年的国谈。在IL-4靶点上,司普奇拜单抗的竞争对手只有赛诺菲的度普利尤单抗。但在适应症上,司普奇拜单抗的竞争对手不少。特异性皮炎有不少特效药,包括乌帕替尼、阿布昔替尼、克立硼罗软膏等,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.